Aspire BioPharma is trading 11.51% down at $7.84, with no clear company-specific catalyst identified for the September 9, 2026 decline.
- The company announced a $10 million share-repurchase authorization on September 9; its corporate name change was reported on September 8, and neither was explicitly linked to the selloff.
- U.S. stocks are modestly lower amid geopolitical tensions, oil above $100, and rate concerns, but the broader-market move does not fully explain the decline.